{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:35:35Z","timestamp":1791326135537,"version":"4.3.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","award":["2121-05-001"],"award-info":[{"award-number":["2121-05-001"]}],"id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ikena Oncology"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Neurofibromatosis type 2 is a genetic disorder that results in the formation and progressive growth of schwannomas, ependymomas, and\/or meningiomas. The NF2 gene encodes the Merlin protein, which links cell cortical elements to the actin cytoskeleton and regulates a number of key enzymes including Group I p21-activated kinases (PAKs), the Hippo-pathway kinase LATS, and mTORC. While PAK1 and PAK2 directly bind Merlin and transmit proliferation and survival signals when Merlin is mutated or absent, inhibition of Group 1 PAKs alone has not proven sufficient to completely stop the growth of NF2-deficient meningiomas or schwannomas <jats:italic>in vivo<\/jats:italic>, suggesting the need for a second pathway inhibitor. As the Hippo pathway is also activated in NF2-deficient cells, several inhibitors of the Hippo pathway have recently been developed in the form of YAP-TEAD binding inhibitors. These inhibitors prevent activation of pro-proliferation and anti-apoptotic Hippo pathway effectors. In this study, we show that PAK inhibition slows cell proliferation while TEAD inhibition promotes apoptotic cell death. Finally, we demonstrate the efficacy of PAK and TEAD inhibitor combinations in several NF2-deficient Schwannoma cell lines.<\/jats:p>","DOI":"10.1371\/journal.pone.0305121","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:54:31Z","timestamp":1722455671000},"page":"e0305121","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5722-025X","authenticated-orcid":true,"given":"Dorothy","family":"Benton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi","family":"Yee Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiia","family":"Karchugina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chernoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"11","key":"pone.0305121.ref001","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115850","article-title":"Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis","volume":"22","author":"R. Tamura","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0305121.ref002","first-page":"vdad041","article-title":"Prospective phase II trial of the dual mTORC1\/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2","volume":"5","author":"JT Jordan","year":"2023","journal-title":"Neurooncol Adv"},{"issue":"2","key":"pone.0305121.ref003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","article-title":"A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas","volume":"133","author":"S Goutagny","year":"2017","journal-title":"J Neurooncol"},{"issue":"19","key":"pone.0305121.ref004","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1158\/0008-5472.CAN-08-0866","article-title":"Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2","volume":"68","author":"C Yi","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"pone.0305121.ref005","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.18632\/oncotarget.2810","article-title":"Group I Paks as therapeutic targets in NF2-deficient meningioma","volume":"6","author":"H-Y Chow","year":"2015","journal-title":"Oncotarget"},{"issue":"40","key":"pone.0305121.ref006","doi-asserted-by":"crossref","first-page":"29105","DOI":"10.1074\/jbc.M113.510933","article-title":"FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated Schwannomas","volume":"288","author":"S Licciulli","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"pone.0305121.ref007","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1021\/acs.jmedchem.6b00638","article-title":"Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window","volume":"59","author":"J Rudolph","year":"2016","journal-title":"J Med Chem"},{"issue":"5","key":"pone.0305121.ref008","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1101\/gad.9.5.534","article-title":"The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation","volume":"9","author":"RW Justice","year":"1995","journal-title":"Genes & Development"},{"issue":"4","key":"pone.0305121.ref009","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1242\/dev.121.4.1053","article-title":"Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase","volume":"121","author":"T Xu","year":"1995","journal-title":"Development"},{"issue":"4","key":"pone.0305121.ref010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.210773.112","article-title":"The Hippo pathway: regulators and regulations","volume":"27","author":"F-X Yu","year":"2013","journal-title":"Genes & Development"},{"issue":"8","key":"pone.0305121.ref011","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","article-title":"YAP\/TAZ upstream signals and downstream responses","volume":"20","author":"A Totaro","year":"2018","journal-title":"Nat Cell Biol"},{"issue":"5","key":"pone.0305121.ref012","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","article-title":"Therapeutic targeting of TEAD transcription factors in cancer","volume":"48","author":"AV Pobbati","year":"2023","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"pone.0305121.ref013","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/brain\/awac342","article-title":"Inhibition of YAP\/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma","volume":"146","author":"L Laraba","year":"2023","journal-title":"Brain"},{"issue":"6","key":"pone.0305121.ref014","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma","volume":"20","author":"TT Tang","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"pone.0305121.ref015","first-page":"vdac072","article-title":"Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2","volume":"4","author":"J Doherty","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"1","key":"pone.0305121.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.990080101","article-title":"A pragmatic approach to the analysis of DNA histograms with a definable G1 peak","volume":"8","author":"JV Watson","year":"1987","journal-title":"Cytometry"},{"issue":"17","key":"pone.0305121.ref017","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/hmg\/ddab106","article-title":"PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2)","volume":"30","author":"E Hawley","year":"2021","journal-title":"Human Molecular Genetics"},{"issue":"23","key":"pone.0305121.ref018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235497","article-title":"New Insights into YAP\/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer","volume":"15","author":"Y Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0305121.ref019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.str.2015.11.005","article-title":"Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway signaling","volume":"24","author":"CL Noland","year":"2016","journal-title":"Structure"},{"issue":"2","key":"pone.0305121.ref020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-021-03699-6","article-title":"Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma","volume":"152","author":"JT Saunders","year":"2021","journal-title":"J Neurooncol"},{"issue":"3","key":"pone.0305121.ref021","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"S Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"6","key":"pone.0305121.ref022","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","article-title":"Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients","volume":"73","author":"KM Slusarz","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0305121.ref023","doi-asserted-by":"crossref","first-page":"1161995","DOI":"10.3389\/ftox.2023.1161995","article-title":"NF2 alteration in mesothelioma","volume":"5","author":"Y Sekido","year":"2023","journal-title":"Front Toxicol"},{"key":"pone.0305121.ref024","article-title":"Simultaneous Inhibition of PI3K and PAK in Preclinical Models of Neurofibromatosis Type 2-related Schwannomatosis","author":"C Fernandez-Valle","year":"2023","journal-title":"Res Sq"},{"issue":"1","key":"pone.0305121.ref025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MAO.0000000000001247","article-title":"Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe","volume":"38","author":"ME Mercado-Pimentel","year":"2017","journal-title":"Otol Neurotol"},{"issue":"2","key":"pone.0305121.ref026","first-page":"93","article-title":"What is synergy?","volume":"41","author":"MC Berenbaum","year":"1989","journal-title":"Pharmacological Reviews"},{"key":"pone.0305121.ref027","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model","volume":"13","author":"B Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"issue":"6","key":"pone.0305121.ref028","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"S. Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"issue":"1\u20132","key":"pone.0305121.ref029","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mrfmmm.2007.07.015","article-title":"Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity","volume":"637","author":"P Lepont","year":"2008","journal-title":"Mutat Res"},{"issue":"8","key":"pone.0305121.ref030","first-page":"8787","article-title":"Characterization of a newly established schwannoma cell line from a sporadic vestibular schwannoma patient","volume":"13","author":"L Xue","year":"2021","journal-title":"American Journal of Translational Research"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:54:58Z","timestamp":1722455698000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305121"}},"subtitle":[],"editor":[{"given":"Mirjam M.","family":"Zegers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0305121","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}